These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pathophysiology of maple syrup urine disease: Focus on the neurotoxic role of the accumulated branched-chain amino acids and branched-chain α-keto acids. Amaral AU; Wajner M Neurochem Int; 2022 Jul; 157():105360. PubMed ID: 35577033 [TBL] [Abstract][Full Text] [Related]
4. Administration of branched-chain amino acids increases the susceptibility to lipopolysaccharide-induced inflammation in young Wistar rats. Wessler LB; de Miranda Ramos V; Bittencourt Pasquali MA; Fonseca Moreira JC; de Oliveira J; Scaini G; Streck EL Int J Dev Neurosci; 2019 Nov; 78():210-214. PubMed ID: 31330240 [TBL] [Abstract][Full Text] [Related]
5. Cerebral Oedema, Blood-Brain Barrier Breakdown and the Decrease in Na(+),K(+)-ATPase Activity in the Cerebral Cortex and Hippocampus are Prevented by Dexamethasone in an Animal Model of Maple Syrup Urine Disease. Rosa L; Galant LS; Dall'Igna DM; Kolling J; Siebert C; Schuck PF; Ferreira GC; Wyse ATS; Dal-Pizzol F; Scaini G; Streck EL Mol Neurobiol; 2016 Aug; 53(6):3714-3723. PubMed ID: 26133302 [TBL] [Abstract][Full Text] [Related]
6. Plasma amino acid and urine organic acid profiles of Filipino patients with maple syrup urine disease (MSUD) and correlation with their neurologic features. Chiong MA; Tan MA; Cordero CP; Fodra EG; Manliguis JS; Lopez CP; Dalmacio LM Mol Genet Metab Rep; 2016 Dec; 9():46-53. PubMed ID: 27761412 [TBL] [Abstract][Full Text] [Related]
7. Serum Markers of Neurodegeneration in Maple Syrup Urine Disease. Scaini G; Tonon T; de Souza CFM; Schuk PF; Ferreira GC; Neto JS; Amorin T; Schwartz IVD; Streck EL Mol Neurobiol; 2017 Sep; 54(7):5709-5719. PubMed ID: 27660262 [TBL] [Abstract][Full Text] [Related]
8. Memantine Improves Memory and Neurochemical Damage in a Model of Maple Syrup Urine Disease. Lemos IDS; Torres CA; Alano CG; Matiola RT; de Figueiredo Seldenreich R; Padilha APZ; De Pieri E; Effting PS; Machado-De-Ávila RA; Réus GZ; Leipnitz G; Streck EL Neurochem Res; 2024 Mar; 49(3):758-770. PubMed ID: 38104040 [TBL] [Abstract][Full Text] [Related]
9. L-Carnitine supplementation decreases DNA damage in treated MSUD patients. Mescka CP; Guerreiro G; Hammerschmidt T; Faverzani J; de Moura Coelho D; Mandredini V; Wayhs CA; Wajner M; Dutra-Filho CS; Vargas CR Mutat Res; 2015 May; 775():43-7. PubMed ID: 25867118 [TBL] [Abstract][Full Text] [Related]
10. Lipid changes in the metabolome of a single case study with maple syrup urine disease (MSUD) after five days of improved diet adherence of controlled branched-chain amino acids (BCAA). Douglas TD; Newby LK; Eckstrand J; Wixted D; Singh RH Mol Genet Metab Rep; 2020 Dec; 25():100651. PubMed ID: 33088714 [TBL] [Abstract][Full Text] [Related]
11. Administration of branched-chain amino acids alters epigenetic regulatory enzymes in an animal model of Maple Syrup Urine Disease. Streck EL; Bussular FP; Wessler LB; Duarte MB; Rezende VL; Rodrigues MS; Torres CA; Lemos IS; Candiotto G; Gava FF; de Oliveira J; Valvassori SS Metab Brain Dis; 2021 Feb; 36(2):247-254. PubMed ID: 33098071 [TBL] [Abstract][Full Text] [Related]
12. Treatment of maple syrup urine disease: Benefits, risks, and challenges of liver transplantation. Deon M; Guerreiro G; Girardi J; Ribas G; Vargas CR Int J Dev Neurosci; 2023 Oct; 83(6):489-504. PubMed ID: 37340513 [TBL] [Abstract][Full Text] [Related]
14. Acute effects of intracerebroventricular administration of α-ketoisocaproic acid in young rats on inflammatory parameters. Rabelo F; Lemos IDS; Dal Toé CP; Casagrande DD; Freitas MLS; Quadra MR; Lima IR; Generoso JS; Michels M; Silveira PCL; Pizzol FD; Streck EL Metab Brain Dis; 2023 Jun; 38(5):1573-1579. PubMed ID: 36897514 [TBL] [Abstract][Full Text] [Related]
15. Branched-chain amino acids (BCAA) administration increases autophagy and the autophagic pathway in brain tissue of rats submitted to a Maple Syrup Urine Disease (MSUD) protocol. Fermo KT; da Silva Lemos I; Farias HR; Rosso MP; Effting PS; Leipnitz G; Streck EL Metab Brain Dis; 2023 Jan; 38(1):287-293. PubMed ID: 36305998 [TBL] [Abstract][Full Text] [Related]
16. Urinary biomarkers of oxidative damage in Maple syrup urine disease: the L-carnitine role. Guerreiro G; Mescka CP; Sitta A; Donida B; Marchetti D; Hammerschmidt T; Faverzani J; Coelho Dde M; Wajner M; Dutra-Filho CS; Vargas CR Int J Dev Neurosci; 2015 May; 42():10-4. PubMed ID: 25680940 [TBL] [Abstract][Full Text] [Related]
17. Muscle-directed AAV gene therapy rescues the maple syrup urine disease phenotype in a mouse model. Greig JA; Jennis M; Dandekar A; Chorazeczewski JK; Smith MK; Ashley SN; Yan H; Wilson JM Mol Genet Metab; 2021; 134(1-2):139-146. PubMed ID: 34454844 [TBL] [Abstract][Full Text] [Related]
18. Total branched-chain amino acids requirement in patients with maple syrup urine disease by use of indicator amino acid oxidation with L-[1-13C]phenylalanine. Riazi R; Rafii M; Clarke JT; Wykes LJ; Ball RO; Pencharz PB Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E142-9. PubMed ID: 14970005 [TBL] [Abstract][Full Text] [Related]
19. Brain Branched-Chain Amino Acids in Maple Syrup Urine Disease: Implications for Neurological Disorders. Xu J; Jakher Y; Ahrens-Nicklas RC Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050626 [TBL] [Abstract][Full Text] [Related]